Hedy Kindler to Mutation
This is a "connection" page, showing publications Hedy Kindler has written about Mutation.
Connection Strength
0.229
-
Integrative Molecular Characterization of Malignant Pleural Mesothelioma. Cancer Discov. 2018 12; 8(12):1548-1565.
Score: 0.075
-
Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma. Eur J Cancer. 2018 01; 89:19-26.
Score: 0.071
-
Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy. Br J Cancer. 2021 02; 124(3):564-566.
Score: 0.022
-
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020 10; 21(10):1353-1365.
Score: 0.022
-
A phase II study of a human anti-PDGFRa monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors. Ann Oncol. 2017 03 01; 28(3):541-546.
Score: 0.017
-
RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. Cancer Biol Ther. 2011 Jul 01; 12(1):9-46.
Score: 0.011
-
Personalized colon cancer care in 2010. Semin Oncol. 2011 Apr; 38(2):284-308.
Score: 0.011